A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Ostergaard, H., Lund, J., Greisen, P.J., Kjellev, S., Henriksen, A., Lorenzen, N., Johansson, E., Roder, G., Rasch, M.G., Johnsen, L.B., Egebjerg, T., Lund, S., Rahbek-Nielsen, H., Gandhi, P.S., Lamberth, K., Loftager, M., Andersen, L.M., Bonde, A.C., Stavenuiter, F., Madsen, D.E., Li, X., Holm, T.L., Ley, C.D., Thygesen, P., Zhu, H., Zhou, R., Thorn, K., Yang, Z., Hermit, M.B., Bjelke, J.R., Hansen, B.G., Hilden, I.(2021) Blood 138: 1258-1268
- PubMed: 34077951 
- DOI: https://doi.org/10.1182/blood.2020010331
- Primary Citation of Related Structures:  
7AHU, 7AHV - PubMed Abstract: 
Hemophilia A is a bleeding disorder resulting from deficient factor VIII (FVIII), which normally functions as a cofactor to activated factor IX (FIXa) that facilitates activation of factor X (FX). To mimic this property in a bispecific antibody format, a screening was conducted to identify functional pairs of anti-FIXa and anti-FX antibodies, followed by optimization of functional and biophysical properties ...